Relationship Between Body Composition, Food Consumption, and Micro and Macronutrients With Gene Expression in Breast Cancer (NUTRIBREAST)

I

Instituto Jalisciense de Cancerologia

Status

Unknown

Conditions

Endocrine Therapy Adverse Reaction
Breast Cancer
Nutrition Disorders
Vitamin D Deficiency
Endocrine Therapy
Obesity

Treatments

Drug: Exemestane
Diagnostic Test: Recurrence
Drug: Tamoxifen
Drug: Anastrozole
Diagnostic Test: Basal

Study type

Observational

Funder types

Other

Identifiers

NCT04389424
1/15

Details and patient eligibility

About

The protocol involves measurement of 25 hidroxy vitamin D, gene expression of cytochrome and vitamin D receptor , endoxifen, tamoxifen, exemestane, and other metobolites related to nutrition and endocrine metabolism.

Enrollment

300 estimated patients

Sex

Female

Ages

18 to 98 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Breast cancer women under endocrine therapy or recurrence of disease after endocrine therapy
  • Signed consent

Exclusion criteria

Mental retardation

Trial design

300 participants in 5 patient groups

Anastrozole
Description:
Breast cancer women with anastrozole treatment
Treatment:
Drug: Anastrozole
Tamoxifen
Description:
Breast cancer women with tamoxifen treatment
Treatment:
Drug: Tamoxifen
Exemestane
Description:
Breast cancer women with exemestane treatment
Treatment:
Drug: Exemestane
Basal
Description:
Breast cancer women luminal type without any endocrine treatment (at initial diagnosis)
Treatment:
Diagnostic Test: Basal
Recurrence
Description:
Breast cancer women luminal type with recurrence of disease during endocrine therapy
Treatment:
Drug: Anastrozole
Drug: Tamoxifen
Diagnostic Test: Recurrence

Trial contacts and locations

0

Loading...

Central trial contact

JOSE ALFONSO CRUZ RAMOS, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems